HECTOR.

Trial name or title	Topotecan plus carboplatin (TC) versus standard therapy with paclitaxel plus carboplatin (PC) or gemcitabine plus carboplatin (GC) or carboplatin plus pegylated doxorubicin (PLDC): a randomised phase III trial of the NOGGO‐AGO‐Germany‐AGO Austria and GEICO‐GCIG intergroup study (HECTOR)
Methods	Phase III multicentre RCT
Participants	550 women with PS ROC.
Interventions	Arm 1:TC Arm 2: GC or PC or PLDC
Outcomes	Primary: PFS Secondary: toxicity
Starting date	Accrual from Feb 2007 to Dec 2009
Contact information	Sehouli@aol.com
Notes	Interim data of the first 200 women were presented at ASCO 2012. However, approx. 78% of control arm received GC and it is not clear how many participants, if any, received the PLDC intervention. We emailed the lead investigator for more information on 13/11/12 and 30/11/12.